TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Arm Label: micronized progesterone; Type: EXPERIMENTAL; Interventions: Drug: micronized progesterone | Arm Label: no utrogestan; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: micronized progesterone; Assigned to Arm(s): micronized progesterone
B: Arm Label: Menotropin/Progesterone vaginal insert; Type: EXPERIMENTAL; Interventions: Drug: Menotropin, Drug: Progesterone vaginal insert, Drug: leuprolide acetate | Arm Label: Menotropin/Progesterone in oil; Type: EXPERIMENTAL; Interventions: Drug: Menotropin, Drug: Progesterone in oil, Drug: leuprolide acetate | Arm Label: Follitropin beta/Progesterone vaginal insert; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone vaginal insert, Drug: Follitropin beta, Drug: leuprolide acetate | Arm Label: Follitropin beta/Progesterone in oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin beta, Drug: Progesterone in oil, Drug: leuprolide acetate | Intervention Type: DRUG; Name: Menotropin; Assigned to Arm(s): Menotropin/Progesterone in oil, Menotropin/Progesterone vaginal insert | Intervention Type: DRUG; Name: Progesterone vaginal insert; Assigned to Arm(s): Follitropin beta/Progesterone vaginal insert, Menotropin/Progesterone vaginal insert | Intervention Type: DRUG; Name: Follitropin beta; Assigned to Arm(s): Follitropin beta/Progesterone in oil, Follitropin beta/Progesterone vaginal insert | Intervention Type: DRUG; Name: Progesterone in oil; Assigned to Arm(s): Follitropin beta/Progesterone in oil, Menotropin/Progesterone in oil | Intervention Type: DRUG; Name: leuprolide acetate; Assigned to Arm(s): Follitropin beta/Progesterone in oil, Follitropin beta/Progesterone vaginal insert, Menotropin/Progesterone in oil, Menotropin/Progesterone vaginal insert
C: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Arm Label: With PGS; Type: EXPERIMENTAL; Interventions: Procedure: IVF/ICSI, Genetic: PGS | Arm Label: Without PGS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: IVF/ICSI, Other: Without PGS | Intervention Type: PROCEDURE; Name: IVF/ICSI; Assigned to Arm(s): With PGS, Without PGS | Intervention Type: GENETIC; Name: PGS; Assigned to Arm(s): With PGS | Intervention Type: OTHER; Name: Without PGS; Assigned to Arm(s): Without PGS
B: Arm Label: Endometrial scratch group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endometrial scratch, Procedure: controlled ovarian hyperstimulation | Arm Label: Assisted hatching group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: assisted hatching, Procedure: controlled ovarian hyperstimulation | Arm Label: ovarian stimulation only group; Type: SHAM_COMPARATOR; Interventions: Procedure: controlled ovarian hyperstimulation | Intervention Type: PROCEDURE; Name: endometrial scratch; Assigned to Arm(s): Endometrial scratch group | Intervention Type: PROCEDURE; Name: assisted hatching; Assigned to Arm(s): Assisted hatching group | Intervention Type: PROCEDURE; Name: controlled ovarian hyperstimulation; Assigned to Arm(s): Assisted hatching group, Endometrial scratch group, ovarian stimulation only group
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: PGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PGS; Assigned to Arm(s): Group A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1
C: Arm Label: Endometrial biopsy arm; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy, Device: Transvaginal ultrasound | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Endometrial biopsy arm | Intervention Type: DEVICE; Name: Transvaginal ultrasound; Assigned to Arm(s): Endometrial biopsy arm
D: Arm Label: Atosiban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atosiban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.
Brief Summary: The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).


Options:
A: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top
D: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: QUIT-PRIMO: Web-Delivered Clinical Microsystem Intervention for Tobacco Control
Brief Summary: This is a randomized control trial to determine the efficacy of a multi-modal intervention in improving smoking cessation processes of care and patient outcomes in community-based primary care practices. Our Overall Goal is to advance science related to the use and impact of the Internet in health services delivery, specifically smoking cessation, by targeting primary care clinical microsystems. A clinical microsystem is defined as the smallest functional healthcare unit. A clinical microsystem is not simply equivalent to a clinical team of doctors and nurses, but also the panel of patients cared for by the providers and the processes of care that are used.


Options:
A: Arm Label: San Francisco Internet Stop Smoking Site; Type: EXPERIMENTAL; Interventions: Behavioral: UCSF/SFGH Internet Stop Smoking Study site | Intervention Type: BEHAVIORAL; Name: UCSF/SFGH Internet Stop Smoking Study site; Assigned to Arm(s): San Francisco Internet Stop Smoking Site
B: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bronx A1c: Bring it Down for Health
Brief Summary: To address and reduce population-attributable risk due to elevated HbA1c, the New York City Department of Health and Mental Hygiene (DOHMH) developed an innovative HbA1c registry, which requires all major laboratories to report HbA1c results electronically. We propose to utilize this registry to conduct a randomized controlled trial addressing the following specific aims: 1) to evaluate the incremental effect of a tiered and tailored, patient-centered telephone intervention, in English and Spanish, on the mean HbA1c levels beyond that achieved with print materials mailed to patients and providers by the DOHMH registry intervention; 2) determine what patient demographic and psychosocial factors mediate the effect of the interventions; and 3) provide estimates of implementation costs of the tiered, tailored telephone intervention for comparison with the print intervention. The study outcome will be change in HbA1c values from the registry records from baseline to one-year post-randomization. A total of 941 individuals with diabetes will be needed to provide 83% power to detect a statistically significant difference (p\<0.05) between groups of at least 0.3% in absolute HbA1c. Intervention cost data will be evaluated for translation of findings and scalability. At study end, we will know the extent to which this intervention will improve metabolic control in a low-income, multi-ethnic sample who are part of the DOHMH HbA1c registry in the South Bronx, New York. These findings will inform public health policies and practices in New York City, as well as other urban areas throughout the nation.


Options:
A: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support
B: Arm Label: Control-usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention paired testing and remote monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose | Intervention Type: BEHAVIORAL; Name: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose; Assigned to Arm(s): Intervention paired testing and remote monitoring
C: Arm Label: Telephonic; Type: EXPERIMENTAL; Interventions: Behavioral: telephonic | Arm Label: Standard registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telephonic | Intervention Type: BEHAVIORAL; Name: telephonic; Assigned to Arm(s): Standard registry, Telephonic
D: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Brief Summary: Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712, Drug: ADT | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: ADT | Intervention Type: DRUG; Name: OPC-34712; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Enhancement Program and medication management | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Health Enhancement Program and medication management; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Different Doses and Schedules of Administration of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Brief Summary: Peripheral Arterial Occlusive Disease (PAOD) is a condition caused by ischemia in the legs due to atherosclerotic disease affecting the larger arteries of the legs. Chronic PAOD can be regarded as a marker of generalized atherosclerosis. PAOD threatens the survival of an extremity and often causes lifelong disablement from a painful leg. The clinical consequences of PAOD include pain on walking (claudication), pain at rest and loss of tissue integrity in the distal limbs.A variety of medical therapies have been investigated for patients with PAOD. There is currently no evidence to suggest that any medical therapy is effective for patients with rest pain and/or ischemic ulcers.

Also, the use of intramuscular angiogenic VEGF-A gene transfer has recently demonstrated a improvement in clinical and hemodynamic status in patients with severe PAOD


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: MESENDO; Type: EXPERIMENTAL; Interventions: Biological: MESENDO | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MESENDO; Assigned to Arm(s): MESENDO | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Different Doses and Schedules of Administration of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Brief Summary: Peripheral Arterial Occlusive Disease (PAOD) is a condition caused by ischemia in the legs due to atherosclerotic disease affecting the larger arteries of the legs. Chronic PAOD can be regarded as a marker of generalized atherosclerosis. PAOD threatens the survival of an extremity and often causes lifelong disablement from a painful leg. The clinical consequences of PAOD include pain on walking (claudication), pain at rest and loss of tissue integrity in the distal limbs.A variety of medical therapies have been investigated for patients with PAOD. There is currently no evidence to suggest that any medical therapy is effective for patients with rest pain and/or ischemic ulcers.

Also, the use of intramuscular angiogenic VEGF-A gene transfer has recently demonstrated a improvement in clinical and hemodynamic status in patients with severe PAOD


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood: Interventional Trial in the COPSAC2010 (Copenhagen Studies on Asthma in Childhood) Birth Cohort
Brief Summary: The aim of this study is to prevent asthma and allergies in childhood by supplementation with fish oil (n-3 fatty acids) to the mother during pregnancy. Paticipants are mother and children participating in the ABC-(Asthma Begins in Childhood)cohort. Mothers are recruited during pregnancy and receive supplement with n-3 fatty acids or olive oil (placebo) from week 24 of gestation to 1 week after delivery. The child is followed with acute and planned visit at the research unit and diagnosis of disease is done in the research unit according to predefined algorithms.


Options:
A: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2
D: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo control | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo control; Assigned to Arm(s): Control

Answer: C